Hôpital Georges Pompidou-APHP, University Paris V, Paris, France.
Am J Cardiol. 2010 Mar 1;105(5):687-93. doi: 10.1016/j.amjcard.2009.10.012. Epub 2009 Dec 7.
The REgistry on Cardiac rhythm disORDers assessing the control of Atrial Fibrillation (RecordAF) is the first worldwide, 1-year observational, longitudinal study of the management of paroxysmal/persistent atrial fibrillation (AF) in recently diagnosed patients. The study was conducted at 532 sites in 21 countries across Europe, America, and Asia; recruitment was completed in April 2008. The primary objectives were to prospectively assess the therapeutic success and clinical outcomes in rhythm- and rate-control strategies. The study design and patient baseline data are reported. A total of 5,814 patients with AF were registered, and 5,604 were eligible for evaluation. Rhythm- and rate-control strategies were applied to 55% and 45% of patients, respectively, at study inclusion. Rhythm-control patients mainly received class III agents (45%) or beta blockers (51%), except for sotalol, and rate-control patients mainly received beta blockers (72%), except for sotalol, or cardiac glycosides (34%). Patients receiving a rhythm-control strategy were younger, had a lower resting heart rate, were more frequently symptomatic, and were more likely to have recently diagnosed AF or paroxysmal AF compared to patients receiving a rate-control strategy. A rate-control strategy was more common in patients with a history of heart failure or valvular heart disease and persistent AF. Rate-control patients more often had previous electrocardiographic evidence of AF and were not in sinus rhythm at inclusion (p <0.01 for both end points). Patients were followed at 6 and 12 months, and changes in therapeutic strategy and clinical outcomes were recorded. In conclusion, the RecordAF study results will provide a global perspective on current AF treatment strategies.
心律失常患者控制心房颤动（RecordAF）注册研究是首个在全球范围内进行的为期 1 年的、观察性的、前瞻性研究，旨在评估新发阵发性/持续性心房颤动（AF）患者的管理策略。该研究在欧洲、美洲和亚洲的 21 个国家的 532 个中心进行；招募工作于 2008 年 4 月完成。主要目的是前瞻性评估节律控制和心率控制策略的治疗成功率和临床结局。现将研究设计和患者基线数据报告如下。共登记了 5814 例 AF 患者，其中 5604 例可评估。在研究入组时，分别有 55%和 45%的患者采用节律控制和心率控制策略。节律控制患者主要应用Ⅲ类药物（45%）或β受体阻滞剂（51%），但不包括索他洛尔；心率控制患者主要应用β受体阻滞剂（72%），但不包括索他洛尔，或地高辛（34%）。与接受心率控制策略的患者相比，接受节律控制策略的患者年龄较小，静息心率较低，症状更频繁，且新发 AF 或阵发性 AF 的可能性更高。有心力衰竭或瓣膜性心脏病病史以及持续性 AF 的患者更常采用心率控制策略。有心率控制策略的患者更常伴有既往心电图 AF 证据，且在纳入时未处于窦性心律（两个终点均为 p<0.01）。患者在 6 个月和 12 个月时进行随访，记录治疗策略的变化和临床结局。总之，RecordAF 研究结果将提供当前 AF 治疗策略的全球视角。
